Shares of Arbutus Biopharma Corporation (NASDAQ:ABUS - Get Free Report) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $3.30 and traded as high as $3.40. Arbutus Biopharma shares last traded at $3.35, with a volume of 764,076 shares changing hands.
Arbutus Biopharma Stock Up 0.8%
The firm has a market capitalization of $633.01 million, a PE ratio of -8.09 and a beta of 1.20. The business has a 50-day moving average price of $3.31 and a 200-day moving average price of $3.30. The company has a quick ratio of 6.01, a current ratio of 6.01 and a debt-to-equity ratio of 0.04.
Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The biopharmaceutical company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.04). Arbutus Biopharma had a negative return on equity of 75.51% and a negative net margin of 1,196.64%. The firm had revenue of $1.76 million for the quarter, compared to analyst estimates of $2.54 million. Equities research analysts forecast that Arbutus Biopharma Corporation will post -0.39 earnings per share for the current fiscal year.
Institutional Trading of Arbutus Biopharma
Several hedge funds have recently modified their holdings of the stock. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Arbutus Biopharma in the second quarter valued at $112,000. Aberdeen Group plc increased its holdings in Arbutus Biopharma by 110.2% in the second quarter. Aberdeen Group plc now owns 982,527 shares of the biopharmaceutical company's stock valued at $3,036,000 after buying an additional 515,144 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in Arbutus Biopharma in the second quarter valued at $122,000. Goldman Sachs Group Inc. increased its holdings in Arbutus Biopharma by 290.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,075,948 shares of the biopharmaceutical company's stock valued at $7,245,000 after buying an additional 1,544,070 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in Arbutus Biopharma by 6.4% in the first quarter. Rhumbline Advisers now owns 200,757 shares of the biopharmaceutical company's stock valued at $701,000 after buying an additional 12,159 shares during the last quarter. 43.79% of the stock is currently owned by institutional investors and hedge funds.
About Arbutus Biopharma
(
Get Free Report)
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.
Featured Stories
Before you consider Arbutus Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arbutus Biopharma wasn't on the list.
While Arbutus Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
